Rocket Doctor AI 2025 Financial Results

Why It Matters

U.S. market entry could dramatically expand Rocket Doctor AI’s revenue base and valuation, making early investors poised for outsized returns if the company secures a NASDAQ listing.

Key Takeaways

• Revenue grew 30% QoQ, reaching $700k in Q4
• Annualized run rate now approx. $3 million, up from $2M
• Majority of growth still Canada‑centric, U.S. revenue remains minimal
• Company positions itself as “Shopify for doctors,” not telehealth
• Potential upside hinges on U.S. market adoption and NASDAQ listing

Summary

Rocket Doctor AI disclosed its 2025 financial results, highlighting a 30% quarter‑over‑quarter revenue increase that lifted fourth‑quarter sales to $700,000. The company now projects an annualized run rate of roughly $3 million, up from the prior $2 million baseline, signaling accelerating growth. The surge is driven primarily by the Canadian market, with U.S. sales still marginal. Management emphasizes that the firm is not a traditional telehealth provider but rather a platform enabling physicians to launch virtual and hybrid practices—essentially a "Shopify for doctors." The narrative also points to a sizable total addressable market and the strategic benefit of a NASDAQ listing, drawing parallels to Aduro’s uplift. In the commentary, the speaker noted, "People think it’s a tele‑health company, which it isn’t," and warned that early investors can acquire substantial shares at current low prices before a potential exchange upgrade. The comparison to Aduro’s share‑price dynamics underscores the perceived upside if U.S. adoption accelerates. If Rocket Doctor AI can translate its Canadian momentum into the United States, the company could experience a valuation jump, especially after a NASDAQ uplist. Investors should monitor U.S. market penetration and any regulatory or partnership developments that could unlock that growth trajectory.

Original Description

Disseminated on Behalf of Rocket Doctor AI. $AIDR $AIRDF

Sign up for my free email list and receive a free E-book, MicroCap Investor.

https://mailchi.mp/556515e42e7c/sign-up-for-mailing-list

Disclaimer

Investment Publishing LLC (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Rocket Doctor AI. issued Investment Publishing’s principal, Mariusz Skonieczny, 400,000 Options, which are each exercisable to acquire one common share of the Company at an exercise price of $0.45 for a period of three years from the date of the grant to provide marketing services for a term of 12 months. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing , including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR+ and SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

Forward Looking Statements

This article contains forward-looking statements about Rocket Doctor AI, which are identified by terms such as "anticipate," "expect," and "project." These statements reflect current views regarding company performance, business goals, healthcare market expectations, and intellectual property development. The statements are based on current business and market expectations. However, they involve various risks and uncertainties, including potential delays, financial difficulties, operational challenges, and problems protecting intellectual property. Additional risks include possible regulatory approval delays, market disruptions, personnel issues, and competitive pressures. Given these risks and uncertainties, actual results may differ significantly from what is described in the forward-looking statements. Readers should not place undue reliance on these statements, which are only valid as of the article's publication date and we undertake no obligation to update.